Research progress of anticoagulant drugs targeting coagulation factor Ⅺ
- VernacularTitle:以凝血因子Ⅺ作为靶点的抗凝血药研究进展
- Author:
Xinwen YUAN
1
;
Zhenyu ZHAO
2
Author Information
1. Dept. of Pharmacy，Tianjin Xiqing Hospital，Tianjin 300380，China
2. NHC Key Laboratory of Hormones and Development，Tianjin Medical University Chu Hsien-I Memorial Hospital，Tianjin Institute of Endocrinology/Tianjin Key Laboratory of Metabolic Diseases，Tianjin 300134，China
- Publication Type:Journal Article
- Keywords:
anticoagulants;
coagulation factor Ⅺ;
thrombosis;
FⅪ inhibitors;
thromboembolic disease
- From:
China Pharmacy
2024;35(17):2165-2170
- CountryChina
- Language:Chinese
-
Abstract:
Anticoagulants are the cornerstone of the prevention and treatment of thromboembolic diseases. Existing parenteral and oral anticoagulants achieve effective control of thrombosis by interfering with key aspects of the coagulation cascade reaction， but this is accompanied by an increased risk of bleeding. FⅪ inhibitors， anticoagulants targeting coagulation factor Ⅺ （FⅪ）， can block the amplification phase of the thrombin generation process by inhibiting FⅪ， reducing thrombogenesis with less impact on normal hemostatic effects， and have become one of the most promising new anticoagulants. There are currently no marketed FⅪ inhibitor drugs， while FⅪ inhibitors in phase Ⅱ or phase Ⅲ clinical trials include 3 classes：antisense oligonucleotide， monoclonal antibody and small molecule inhibitors. In addition， most of the natural inhibitors and nucleic acid aptamers targeting FⅪ are under preclinical development. As new target drugs for anticoagulation therapy， FⅪ inhibitors are expected to become a safer and more effective therapeutic option， compensating for the limitations of current anticoagulants and providing patients with more effective thromboprophylaxis and therapeutic options while reducing the risk of bleeding.
